Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Sonpavde G, et al. Among authors: aparicio am. Urol Oncol. 2011 Nov-Dec;29(6):682-9. doi: 10.1016/j.urolonc.2009.09.015. Epub 2009 Dec 3. Urol Oncol. 2011. PMID: 19959380 Clinical Trial.
Hypomethylating agents for urologic cancers.
Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G. Alva AS, et al. Among authors: aparicio am. Future Oncol. 2011 Mar;7(3):447-63. doi: 10.2217/fon.11.9. Future Oncol. 2011. PMID: 21417907 Review.
Epigenetics in prostate cancer.
Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Albany C, et al. Among authors: aparicio am. Prostate Cancer. 2011;2011:580318. doi: 10.1155/2011/580318. Epub 2011 Nov 30. Prostate Cancer. 2011. PMID: 22191037 Free PMC article.
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Li L, et al. Among authors: aparicio am. Sci Signal. 2014 May 20;7(326):ra47. doi: 10.1126/scisignal.2005070. Sci Signal. 2014. PMID: 24847116 Free PMC article.
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Campbell MT, et al. Clin Genitourin Cancer. 2015 Jun;13(3):218-24. doi: 10.1016/j.clgc.2014.10.004. Epub 2014 Oct 24. Clin Genitourin Cancer. 2015. PMID: 25465491 Free PMC article. Clinical Trial.
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Corn PG, et al. Among authors: aparicio am. Lancet Oncol. 2019 Oct;20(10):1432-1443. doi: 10.1016/S1470-2045(19)30408-5. Epub 2019 Sep 9. Lancet Oncol. 2019. PMID: 31515154 Free PMC article. Clinical Trial.
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.
Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. Corn PG, et al. Among authors: aparicio am. Clin Cancer Res. 2020 Mar 1;26(5):990-999. doi: 10.1158/1078-0432.CCR-19-2389. Epub 2020 Jan 15. Clin Cancer Res. 2020. PMID: 31941830 Clinical Trial.
124 results